ReviewInternational journal of clinical practice2008
The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature review.
Review in International journal of clinical practice, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Statistical Methods for Adjusting Estimates of Treatment Effectiveness for Patient Nonadherence in the Context of Time-to-Event Outcomes and Health Technology Assessment: A Systematic Review of Methodological Papers.Medical decision making : an international journal of the Society for Medical Decision Making · 2019Pooled it
- Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Guideline
- Single-pill vs free-equivalent combination therapies for hypertension: a meta-analysis of health care costs and adherence.Journal of clinical hypertension (Greenwich, Conn.) · 2011Pooled it
- Prevalence and Management of Drug-Related Problems in Chronic Kidney Disease Patients by Severity Level: A Subanalysis of a Cluster Randomized Controlled Trial in Community Pharmacies.Journal of managed care & specialty pharmacy · 2018Trial
- Cost-effectiveness of nurse practitioner/community health worker care to reduce cardiovascular health disparities.The Journal of cardiovascular nursing · 2014Trial
- Trial
- Availability and Price Variations of Commonly Used Cardiovascular Medicines at Community and Hospital Pharmacies in Gondar Town, Northwest Ethiopia.BioMed research international · 2024Article
- Real price of health-experiences of out-of-pocket costs in Australia: protocol for a systematic review.BMJ open · 2022Article
- Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2021Article
- The Impact of Prescription Medication Cost Coverage on Oral Medication Use for Hypertension and Type 2 Diabetes Mellitus.Healthcare policy = Politiques de sante · 2020Article
- Article
- Integrated care for the management of ageing-related non-communicable diseases: current gaps and future directions.Aging clinical and experimental research · 2020Article
- Article
- Article
- Treatment of Stable Angina with a New Fixed-Dose Combination of Ivabradine and Metoprolol: Effectiveness and Tolerability in Routine Clinical Practice.Cardiology and therapy · 2017Article
- Improving Adherence to Treatment and Reducing Economic Costs of Hypertension: The Role of Olmesartan-Based Treatment.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2017Review
- An upper and lower bound of the Medication Possession Ratio.Patient preference and adherence · 2017Article
- Understanding adherence-related beliefs about medicine amongst patients of South Asian origin with diabetes and cardiovascular disease patients: a qualitative synthesis.BMC endocrine disorders · 2016Article
- Medication Adherence and the Occurrence of Complications in Patients with Newly Diagnosed Hypertension.Korean circulation journal · 2016Article
- Systematic review of adherence rates by medication class in type 2 diabetes: a study protocol.BMJ open · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo review studies on the cost consequences of compliance and/or persistence in cardiovascular disease (CVD) and related conditions (hypertension, dyslipidaemia, diabetes and heart failure) published since 1995, and to evaluate the effects of noncompliance on healthcare expenditure and the cost-effectiveness of pharmaceutical interventions.
methodsEnglish language papers published between January 1995 and February 2007 that examined compliance/persistence with medication for CVD or related conditions, provided an economic evaluation of pharmacological interventions or cost analysis, and quantified the cost consequences of noncompliance, were identified through database searches. The cost consequences of noncompliance were compared across studies descriptively.
resultsOf the 23 studies identified, 10 focused on hypertension, seven on diabetes, one on dyslipidaemia, one on coronary heart disease, one on heart failure and three covered multiple diseases. In studies assessing drug costs only, increased compliance/persistence led to increased drug costs. However, increased compliance/persistence increased the effectiveness of treatment, leading to a decrease in medical events and non-drug costs. This offset the higher drug costs, leading to savings in overall treatment costs. In studies evaluating the effect of compliance/persistence on the cost-effectiveness of pharmacological interventions, increased compliance/persistence appeared to reduce cost-effectiveness ratios, but the extent of this effect was not quantified.
conclusionsNoncompliance with cardiovascular and antidiabetic medication is a significant problem. Increased compliance/persistence leads to increased drug costs, but these are offset by reduced non-drug costs, leading to overall cost savings. The effect of noncompliance on the cost-effectiveness of pharmacological interventions is inconclusive and further research is needed to resolve the issue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.